Počet záznamů: 1
Concurrent versus Sequential Chemoradiotherapy with Cisplatin and Vinorelbine in Locally Advanced Non-Small Cell Lung Cancer: A Randomized Study
- 1.
SYSNO ASEP 0105221 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Concurrent versus Sequential Chemoradiotherapy with Cisplatin and Vinorelbine in Locally Advanced Non-Small Cell Lung Cancer: A Randomized Study Překlad názvu Randomizovaná studie lokálně pokročilého nemalobuněčného nádoru plic - paralelní versus sekvenční aplikace chemoterapie Cisplatinou a Vinorelbinem Tvůrce(i) Zatloukal, P. (CZ)
Petruželka, L. (CZ)
Zemanová, M. (CZ)
Havel, L. (CZ)
Janků, F. (CZ)
Judas, L. (CZ)
Kubík, A. (CZ)
Křepela, E. (CZ)
Fiala, P. (CZ)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCIDZdroj.dok. Lung Cancer. - : Elsevier - ISSN 0169-5002
Roč. 46, - (2004), s. 87-98Poč.str. 12 s. Jazyk dok. eng - angličtina Země vyd. IE - Irsko Klíč. slova concurrent chemoradiotherapy ; sequential chemoradiotherapy ; locally advanced non-small cell lung cancer ; cisplatin ; vinorelbine Vědní obor RIV BB - Aplikovaná statistika, operační výzkum CEZ AV0Z1030915 - UIVT-O UT WOS 000224326500010 EID SCOPUS 4444293137 DOI https://doi.org/10.1016/j.lungcan.2004.03.004 Anotace This study compared the safety and efficacy of concurrent and sequential CRT, with chemotherapy (CT) consisting of a cisplatin and vinorelbine regimen, in patients with locally advanced NSCLC. In the concurrent arm (arm A), RT was started on day 4 of cycle 2; whilst in the sequential arm (arm B), RT started within 2 weeks after completion of CT. Fifty-two patients were randomized to concurrent treatment and 50 to the sequential schedule. Overall survival was significantly longer in arm A (median survival 16.6 months) versus arm,B (median survival 12.9 months) (P = 0.023 by means of log-rank test; hazard ratio HR = 0.61, 95% CI of FIR (0.39-0.93)), and time to progression (TTP) was also significantly longer in arm A (median time to progression 11.9 months) versus arm B (median time to progression 8.5 months) (P = 0.024 by means of log-rank test; HR = 0.62, 95% Cl of HR (0.38-0.93)). Pracoviště Ústav informatiky Kontakt Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Rok sběru 2005
Počet záznamů: 1